Assertio Holdings, Inc. ("Assertio") (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close.

Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.

Assertio Holdings showed Q1 2023 net product sales increase of 18%, despite reporting a net loss due to increased expenses. Assertio's growth strategy involves expanding product range through ...

Assertio Holdings, Inc. is proactively engaging with investors by announcing the release date for its fourth quarter and full year 2024 financial results, which can enhance transparency and trust. The ...

LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (ASRT) (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to ...

Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Assertio (ASRT) is a stock that can certainly grab the attention of many investors, ...

CEO Brendan O'Grady stated that "our first quarter financial results... are in line with the full-year 2025 net product sales and adjusted EBITDA expectations that were set forth during the March ...

LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today ...